PRR Promotes Obesity Related Hypertension via alpha-ENaC
PRR 通过 alpha-ENaC 促进肥胖相关高血压
基本信息
- 批准号:9327492
- 负责人:
- 金额:$ 6.4万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2017
- 资助国家:美国
- 起止时间:2017-07-01 至 2019-06-30
- 项目状态:已结题
- 来源:
- 关键词:AldosteroneAmilorideAngiotensinsCardiovascular systemChronicComplexDiabetic NephropathyDistalDistal convoluted renal tubule structureDuct (organ) structureDuctal Epithelial CellElementsEpidemicExcretory functionExpenditureFRAP1 geneGlucocorticoidsHealthHealthcareHigh Fat DietHypertensionImpairmentIn VitroInactive ReninInflammationInflammatoryKidneyKnockout MiceKnowledgeLaboratoriesMediator of activation proteinMineralocorticoidsModernizationMolecularMorbidity - disease rateMusNephronsObesityObesity Related HypertensionOutcomeOutcomes ResearchPathogenesisPathway interactionsPhosphorylationPhosphotransferasesPlayPrevalencePreventionPrevention strategyProcessPropertyProtein IsoformsProteinsRenal functionReninRenin-Angiotensin-Aldosterone SystemReverse Transcriptase Polymerase Chain ReactionRoleSerumSignal PathwaySignal TransductionSmall Interfering RNASocietiesSodiumSodium ChannelSodium ChlorideStructureStudy modelsSystemTechniquesTestingUp-RegulationWeight GainWestern BlottingWorkcombatcytokineepithelial Na+ channelin vitro Modelin vivomesangial cellmortalitynew therapeutic targetnovelnovel strategiesnovel therapeutic interventionobesity treatmentpreventreceptorreceptor expressionreceptor functiontherapy developmenttreatment strategy
项目摘要
Project Summary
Hypertension is a direct consequence of obesity and one whose prevalence is increasing rapidly with
the growing obesity epidemic. Hypertension also contributes significantly to morbidity and mortality in today’s
society while increasing healthcare expenditures. However, our knowledge of the pathophysiologic changes in
obesity which promote hypertension remains incomplete. Better understanding these processes is crucial to
devising new treatment strategies.
Obesity related hypertension is in large part due to increased sodium retention which in turn occurs
through changes in expression and activity of sodium channels in the nephron. ENaC is one such important
channel in the distal convoluted tubules and collecting ducts. While several mediators such as increased
angiotensin II (Ang II), mineralocorticoid activity, and inflammatory cytokines have been implicated in
increasing ENaC activity in the setting of obesity, we believe that additional factors may be involved. The
(pro)renin receptor (PRR) is a protein expressed in multiple kidney structures including the distal nephron and
whose expression is increased by inflammation. Although initially proposed as a component of the renin-
agniotensin-aldosterone system (RAAS) that increases activity of renin and prorenin, PRR is now known to
have RAAS independent intracellular signaling properties. This includes activation of the PI3K/Akt/mTOR
pathway. Recent work by our laboratory and others have demonstrated an Ang II independent ability of PRR
to upregulate the α-ENaC subunit under normal and low salt conditions. What is not known, however, is
whether this relationship plays a significant role in obesity related hypertension.
The central hypothesis of this project is therefore that, in obesity, increased renal PRR upregulates α-
ENaC expression and activity, leading to sodium retention and promoting hypertension. Two specific aims are
proposed. Aim 1 will test whether PRR induces hypertension through α-ENaC during obesity using an
inducible nephron specific PRR knockout mouse. Aim 2 will test in mouse inner medullary collecting duct cells
whether inflammatory cytokines that are present in obesity increase PRR expression, leading to increased
ENaC activity via the PI3K/Akt/mTOR/serum and glucocorticoid-inducible kinase isoform 1 (SGK-1) signaling
pathway.
The knowledge gained from the proposed studies could potentially help develop exciting new
therapeutic strategies for prevention and treatment of obesity induced hypertension.
项目总结
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Silas A Culver其他文献
Dopamine-Secreting Carotid Body Paraganglioma in a Patient With SDHB Mutation
SDHB 突变患者的多巴胺分泌性颈动脉体副神经节瘤
- DOI:
- 发表时间:
2024 - 期刊:
- 影响因子:0
- 作者:
Katherine Mustafa;Sara Zadeh;Silas A Culver - 通讯作者:
Silas A Culver
Silas A Culver的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Silas A Culver', 18)}}的其他基金
Role of Atp6ap2 in renal proximal tubule lipotoxicity
Atp6ap2 在肾近曲小管脂毒性中的作用
- 批准号:
10591837 - 财政年份:2023
- 资助金额:
$ 6.4万 - 项目类别:
相似海外基金
Repurposing Amiloride into Breast Cancer Drugs with a Dual-Targeting Mechanism
将阿米洛利重新用于具有双靶向机制的乳腺癌药物
- 批准号:
nhmrc : 1100432 - 财政年份:2016
- 资助金额:
$ 6.4万 - 项目类别:
Project Grants
Repurposing Amiloride into Breast Cancer Drugs with a Dual-Targeting Mechanism
将阿米洛利重新用于具有双靶向机制的乳腺癌药物
- 批准号:
nhmrc : GNT1100432 - 财政年份:2016
- 资助金额:
$ 6.4万 - 项目类别:
Project Grants
Amiloride promotes oligodendrocyte survival and remyelination after spinal cord injury in rats
阿米洛利促进大鼠脊髓损伤后少突胶质细胞存活和髓鞘再生
- 批准号:
26861215 - 财政年份:2014
- 资助金额:
$ 6.4万 - 项目类别:
Grant-in-Aid for Young Scientists (B)
Effect of amiloride on endoplasmic reticulum stress response in the injured spinal cord of rats
阿米洛利对脊髓损伤大鼠内质网应激反应的影响
- 批准号:
25462311 - 财政年份:2013
- 资助金额:
$ 6.4万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Novel target of amiloride analogues - picornaviral RNA polymerase
阿米洛利类似物的新靶点——小RNA病毒RNA聚合酶
- 批准号:
DP0987855 - 财政年份:2009
- 资助金额:
$ 6.4万 - 项目类别:
Discovery Projects
AMILORIDE FOR ERADICATION OF BURKHOLDERIA DOLOSA
阿米洛利用于根除伯克霍尔德氏菌
- 批准号:
7607305 - 财政年份:2007
- 资助金额:
$ 6.4万 - 项目类别:
EFFICACY OF AMILORIDE AND HYPERTONIC SALINE IN CYSTIC FIBROSIS
阿米洛利和高渗盐水治疗囊性纤维化的疗效
- 批准号:
7200178 - 财政年份:2004
- 资助金额:
$ 6.4万 - 项目类别:
Efficacy of Amiloride and Hypertonic Saline in Cystic Fibrosis
阿米洛利和高渗盐水治疗囊性纤维化的疗效
- 批准号:
6980600 - 财政年份:2003
- 资助金额:
$ 6.4万 - 项目类别:
Effect of amiloride and gurmarin on taste receptor cells
阿米洛利和古马林对味觉受体细胞的影响
- 批准号:
6651947 - 财政年份:2002
- 资助金额:
$ 6.4万 - 项目类别:
Effect of amiloride and gurmarin on taste receptor cells
阿米洛利和古马林对味觉受体细胞的影响
- 批准号:
6622339 - 财政年份:2002
- 资助金额:
$ 6.4万 - 项目类别: